Cargando…
Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report
Hepatocellular carcinoma (HCC) is a tumor with a high degree of malignancy. Patients have poor outcomes and short survival times, especially after progression to first-line systemic therapy. Regorafenib is the standard second-line treatment for HCC, but there is no conclusive evidence that regorafen...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597686/ https://www.ncbi.nlm.nih.gov/pubmed/37881484 http://dx.doi.org/10.3389/fonc.2023.1256137 |